Skip to main content
Premium Trial:

Request an Annual Quote

Stalicla Raises $17.4M Series B Financing to Develop Precision Medicines for Autism

NEW YORK – Stalicla on Tuesday announced it has closed a $17.4 million Series B funding round, which the biopharmaceutical firm said it will put toward advancing its pipeline of precision therapeutics for neuropsychiatric and neurological disorders, starting with autism spectrum disorder.

The Series B round was led by SPRIM Global Investments and other investors and includes a $3.8 million credit facility.

Geneva, Switzerland-based Stalicla will use proceeds from the financing to prepare for a Phase II trial of STP1, a therapy for a subgroup of patients with autism spectrum disorder, called ASD-Phen1, that was identified by the firm's platform. STP1 is a combination therapy involving the anti-inflammatory and PDE4/3 inhibitor ibudilast and the NKCC1 antagonist bumetanide. It's designed to address biological dysfunctions associated with ASD-Phen1, according to Stalicla.

Stalicla is also working to bolster the data package supporting its second precision medicine within autism spectrum disorder, STP2, for another subgroup it has identified, dubbed ASD-Phen2. Stalicla acquired rights to the therapy, a stabilized synthetic form of sulforaphane, from Evgen Pharma in October 2022, specifically for neurodevelopmental disorders.

Stalicla said that, to support advancement of these precision therapeutics, it plans to strengthen its management team and board of directors.